SEC Form 4 · accession 0001661181-18-000045
Organogenesis Holdings Inc. · ORGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Walthall
Officer — Exec. VP, Strat. & Mkt Dev.
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 8:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001661181
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $3.46 | Dec 10, 2018 | A | 85,710 | A | — | May 4, 2027 | Common Stock | 85,710 | 85,710 | D |
| Stock Option (Right to Buy)F4,F3 | $3.46 | Dec 10, 2018 | A | 203,000 | A | — | May 4, 2027 | Common Stock | 203,000 | 203,000 | D |
Explanation of responses
- F1100% of the shares subject to this option are fully vested and exercisable.
- F2Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 42,222 shares of common stock of Organogenesis for $7.01 per share.
- F3The shares underlying the option shall vest 20% annually beginning on December 31, 2018.
- F4Received in connection with the Merger in exchange for an option to acquire 100,000 shares of common stock of Organogenesis for $7.01 per share.